Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Свободные комбинации ингаляционных глюкокортикостероидов и пролонгированных ингаляционных b2-агонистов в терапии бронхиальной астмы: результаты российских клинических исследований
Свободные комбинации ингаляционных глюкокортикостероидов и пролонгированных ингаляционных b2-агонистов в терапии бронхиальной астмы: результаты российских клинических исследований
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Чучалин А.Г., Уханова О.П., Шутов Ю.Е. и др. Открытое проспективное наблюдательное исследование эффективности и безопасности свободной комбинации Форадила Аэролайзера и ингаляционного глюкокортикостероида у больных бронхиальной астмой. Атмосфера. Пульмонология и аллергология. 2009; 4: 26–32.
2. Чучалин А.Г., Визель А.А., Лещенко И.В. и др. Результаты российского наблюдательного исследования ФРИСТАЙЛ (ФоРадил КомбИ: эффективноСТь, безопАсность и комплаЙнс у пациентов с бронхиаЛьной астмой). Атмосфера. Пульмонология и аллергология. 2011; 2 (41): 2–7.
3. Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sci 1993.
4. Barnes PJ. Effects of b2-agonists and steroids on b2-adrenoreceptor. Eur Respir Rev 1998; 8 (55): 210–5.
5. Barnes PJ. Clinical outcome of adding long-acting b-agonists to inhaled corticosteroids. Respir Med 2001; 95 (Suppl. B): S12–S16.
6. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. Eur Respir J 2002; 19: 182–91.
7. Bouros D, Bachlitzanakis N, Kottakis J et al. Formoterol and beclomethasone versus higher doses beclomethasone as maintenance therapy in adult asthma. Eur Respir J 1999; 14: 627–32.
8. Chowdhury BA et al. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; 362 (13): 1169–71.
9. Dahl R, Greefhost LARM, Nowak D et al. Inhaled formoterol dry in cronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778–84.
10. Gessner C et al. Miflonide®/Foradil® via Aerolizer® сompared with оther аnti-inflammatory and antiobstructive therapeutiс regimens. Pneumologie 2003; 57: 137–43.
11. Hall Ian P. Hall. b2-Adrenoreceptor agonists. In: Barnes PJ. Asthma and COPD Basic Mechanisms and Clinical Management, 1st ed. Copyright© 2002, Academic Press.
12. Kaik G et al. Sequential Flexible Therapy with Formoterol (Foradil®) plus Budesonide (Miflonide®) Versus a Fixed Combination of Salmeterol and Fluticasone (Seretide®) in Asthma Self-management. Europ Resp J 2002; 20 (Suppl. 38): 388s.
13. Mak JCW, Nishikawa M, Barnes PJ. Glucocorticoids increase b2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 268: L41–6.
14. Mak JCW, Nishikawa M, Shirasaki H et al. Protective effects of a glucocorticoid on downregulation of pulmonary b2-adrenergic receptors in vivo. J Clin Invest 1995; 96: 99–106.
15. Mitchell C, Jenkins C, Scicchitano R et al. Formoterol (Foradil®) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulm Pharmacol Ther 2003; 16: 299–306.
16. Nials AT, Ball DI, Butchers PR et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994; 251: 127–35.
17. O’Connor BJ, Alkinan SL, Barnes PJ. Tolerance to the non-bronchodilatator effects of inhaled b2-agonists in asthma. N Engl J Med 1992.
18. Palmquist M et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999.
19. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir 1999.
20. van Noord JA, Smeets JJ, Raaijmakers JA et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9: 1684–8.
2. Чучалин А.Г., Визель А.А., Лещенко И.В. и др. Результаты российского наблюдательного исследования ФРИСТАЙЛ (ФоРадил КомбИ: эффективноСТь, безопАсность и комплаЙнс у пациентов с бронхиаЛьной астмой). Атмосфера. Пульмонология и аллергология. 2011; 2 (41): 2–7.
3. Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of highly potent and selective agonist bronchodilatator. Life Sci 1993.
4. Barnes PJ. Effects of b2-agonists and steroids on b2-adrenoreceptor. Eur Respir Rev 1998; 8 (55): 210–5.
5. Barnes PJ. Clinical outcome of adding long-acting b-agonists to inhaled corticosteroids. Respir Med 2001; 95 (Suppl. B): S12–S16.
6. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. Eur Respir J 2002; 19: 182–91.
7. Bouros D, Bachlitzanakis N, Kottakis J et al. Formoterol and beclomethasone versus higher doses beclomethasone as maintenance therapy in adult asthma. Eur Respir J 1999; 14: 627–32.
8. Chowdhury BA et al. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; 362 (13): 1169–71.
9. Dahl R, Greefhost LARM, Nowak D et al. Inhaled formoterol dry in cronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778–84.
10. Gessner C et al. Miflonide®/Foradil® via Aerolizer® сompared with оther аnti-inflammatory and antiobstructive therapeutiс regimens. Pneumologie 2003; 57: 137–43.
11. Hall Ian P. Hall. b2-Adrenoreceptor agonists. In: Barnes PJ. Asthma and COPD Basic Mechanisms and Clinical Management, 1st ed. Copyright© 2002, Academic Press.
12. Kaik G et al. Sequential Flexible Therapy with Formoterol (Foradil®) plus Budesonide (Miflonide®) Versus a Fixed Combination of Salmeterol and Fluticasone (Seretide®) in Asthma Self-management. Europ Resp J 2002; 20 (Suppl. 38): 388s.
13. Mak JCW, Nishikawa M, Barnes PJ. Glucocorticoids increase b2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 268: L41–6.
14. Mak JCW, Nishikawa M, Shirasaki H et al. Protective effects of a glucocorticoid on downregulation of pulmonary b2-adrenergic receptors in vivo. J Clin Invest 1995; 96: 99–106.
15. Mitchell C, Jenkins C, Scicchitano R et al. Formoterol (Foradil®) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulm Pharmacol Ther 2003; 16: 299–306.
16. Nials AT, Ball DI, Butchers PR et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994; 251: 127–35.
17. O’Connor BJ, Alkinan SL, Barnes PJ. Tolerance to the non-bronchodilatator effects of inhaled b2-agonists in asthma. N Engl J Med 1992.
18. Palmquist M et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999.
19. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir 1999.
20. van Noord JA, Smeets JJ, Raaijmakers JA et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9: 1684–8.
Авторы
Н.П.Княжеская
Кафедра пульмонологии ФУВ ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздравсоцразвития РФ, Москва
Кафедра пульмонологии ФУВ ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздравсоцразвития РФ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.